# TAVI-leveringen vergelijkbaar bij tricuspidale, bicuspidale en bioprosthetische kleppen — COMPARE-TAVI 1

*geplaatst 2026-09-28 · Algemeen · Scandinavian cardiovascular journal : SCJ · doi 10.1080/14017431.2026.2704938 · https://hartvaat.nl/2026/12/01/tavi-leveringen-vergelijkbaar-bij-tricuspidale-bicuspidale-en-bioprosthetische-k/*

In een observationele subgroupanalyse van de COMPARE-TAVI 1-cohort vergeleken onderzoekers de 30-dagen- en 1-jaarsuitkomsten van TAVI bij patiënten met een tricuspidale, bicuspidale of bioprosthetische aortaklep. De procedurele resultaten, sterfte en bloedingen waren vergelijkbaar tussen de groepen, hoewel bij bicuspidale kleppen vaker een beroep en bij bioprosthetische kleppen vaker een nieuwe pacemaker nodig was. Deze bevindingen bevestigen dat TAVI veilig en effectief is ongeacht de onderliggende klepanatomie, wat de besluitvorming voor interventiecardiologen ondersteunt.

## English: Transcatheter aortic valve implantation in patients with tricuspid, bicuspid and bioprosthetic valves: observations from COMPARE-TAVI 1.

In an observational subgroup analysis of the COMPARE-TAVI 1 cohort, researchers compared 30-day and 1-year outcomes of TAVI in patients with tricuspid, bicuspid, or bioprosthetic aortic valves. Procedural success, mortality, and bleeding rates were similar across all three anatomies, although bicuspid valves were associated with a higher 30-day stroke rate and bioprosthetic valves with fewer new pacemaker implants. These findings reinforce that TAVI delivers consistent safety and efficacy regardless of underlying valve morphology, supporting its broad applicability in clinical practice.

## Abstract (original, from the publication)

Background. Transcatheter aortic valve implantation (TAVI) is most extensively documented for the treatment of aortic stenosis in patients with tricuspid valves. To compare the 30-day and 1-year outcomes after TAVI in patients with tricuspid, bicuspid and bioprosthetic valves who participated in the COMPARE-TAVI 1 trial. Methods. In COMPARE-TAVI 1, all-comer patients treated with transfemoral TAVI were randomized to treatment with one of two balloon-expandable valves. In this study, these patients were divided into three groups based on valve anatomy. 30-day and 1-year outcomes among patients with bicuspid and bioprosthetic valves (surgical or transcatheter) were compared with outcomes among patients with tricuspid valves. Results. Patients with tricuspid valves (N = 892, median 82 years) were slightly older than patients with bicuspid (N = 98, median 78 years) and bioprosthetic (N = 40, median 80 years) valves. Procedural outcomes were similar. There were no differences in death or bleeding at 30 days, nor in death, myocardial infarction, percutaneous revascularization, or endocarditis at 1 year. Stroke was more frequent among patients with bicuspid valves at 30 days (n = 7), while new pacemaker was less frequent among patients with bioprosthetic valves at 30 days (n = 0). The need for reoperation was more frequent among patients with bicuspid valves (n = 3). Conclusions. In this observational study performed within the COMPARE-TAVI 1 cohort, patients with tricuspid, bicuspid or bioprosthetic valves had similar outcomes. No patients with bioprosthetic valves had a new pacemaker within 30 days after TAVI. Clinical trial registration. ClinicalTrials.gov: NCT04443023.

Auteurs: Troels Thim, Henrik Nissen, Phillip Freeman, Jordi Sanchez Dahl, Evald Høj Christiansen, Michala Norsell, Ashkan Eftekhari, Bjarne Linde Nørgaard, Christian Alcaraz Frederiksen, Henrik Ølholm Vase, Julia Ellert, Kristian Altern Øvrehus, Mariann Tang, Christian Juhl Terkelsen

---
Bron: Scandinavian cardiovascular journal : SCJ, https://doi.org/10.1080/14017431.2026.2704938. Bijgewerkt 2026-09-22T00:51:14Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.